. Assessment of anti-respiratory syncytial virus (anti-RSV) IgG expression in neonatal mice. (A) Kinetics of anti-RSV IgG. Chimpanzee adenovirus type 7 vector (AdC7) expressing murine anti-RSV antibody (AdC7αRSV) or AdC7 with green fluorescent protein but without transgene expression (AdC7GFP) (3 × 10 10 pu each) was intranasally administered to 1-day-old BALB/c mice. Serum was collected at 4, 7 and 9 weeks after the administration and titers were measured by ELISA. The titers in mice that had received AdC7αRSV are shown as mean  SEM of 7 mice per group. (B) Anti-RSV IgG in the serum and lung homogenate supernatants after 14 weeks following Ad vector administration. AdC7αRSV (3 × 10 10 or 6 × 10 10 pu) or AdC7GFP (3 × 10 10 pu) was intranasally administered to 1-day-old BALB/c mice. Serum and Lungs were collected 14 weeks after the administration and titers were measured by ELISA. The titers in mice that had received AdC7αRSV are shown with mean  SEM. Figure S2 . Protection against RSV infection 10 weeks following AdC7αRSV administration to neonatal mice. AdC7αRSV or AdC7GFP (7 × 10 10 pu) were intranasally administered to 1-day-old BALB/c mice followed by RSV rA2-L19 (5 × 10 6 pfu) challenge at 10 weeks of age. (A) Anti-RSV IgG titers in the serum before the RSV challenge. Serum was collected at 4 and 8 weeks after the administration of AdC7αRSV and titers were measured by ELISA. The titers in mice that had received AdC7αRSV are shown with mean  SEM. (B) RSV viral loads in the lungs 4 days after the RSV challenge by plaque assay. Titers are shown with mean  SEM.
